Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-05-31
2009-06-02
Seaman, D. Margaret (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C546S119000
Reexamination Certificate
active
07541367
ABSTRACT:
The present invention is directed to novel 3-benzoimidazolyl-pyrazolopyridine compounds of formula (I):and pharmaceutically acceptable forms thereof and their synthesis and use as inhibitors of serine-threonine protein kinases and tyrosine protein kinases and interactions thereof.
REFERENCES:
patent: 5474765 (1995-12-01), Thorpe
patent: 5762918 (1998-06-01), Thorpe
patent: 5855866 (1999-01-01), Thorpe et al.
patent: 5902795 (1999-05-01), Toole et al.
patent: 6288082 (2001-09-01), Wissner et al.
patent: 6335344 (2002-01-01), Schnur et al.
patent: 6342219 (2002-01-01), Thorpe et al.
patent: 6413971 (2002-07-01), Arnold et al.
patent: 2005/0009876 (2005-01-01), Bhagwat et al.
patent: WO 01/02369 (2001-01-01), None
patent: WO 01/53268 (2001-07-01), None
patent: WO 03/004488 (2003-01-01), None
patent: WO 03/045949 (2003-06-01), None
patent: WO 2005/000303 (2005-01-01), None
patent: WO 2005/009997 (2005-02-01), None
Straub et al., Bioorganic & Medicinal Chemistry Letters (2001),11(6), 781-784.
International Search Report, PCT/US06/21097, Oct. 3, 2006.
Klijn J.G.M. et al, “The clinical significance of epidermal growth factor receptor (EGF-R) in human breast cancer: a review on 5232 patients”,Endocrine Reviews, 1992, vol. 13, pp. 3-17.
Salomon D et al.; “The erbB family of receptors and their ligands: Multiple targets for therapy”,Signal, 2001, vol. 2, pp. 4-11.
Ekstrand A.J. et al, “Amplified and rearranged epidermal growth factor receptor genes in human glioblastomas reveal deletions of sequences encoding portions of the N-and/or C-terminal tails”,Proc. Acad. Natl. Sci. USA, 1992, vol. 89, pp. 4309-4313.
Wikstrand C.J., “Monoclonal antibodies against EGFRvIII are tumor specific and react with breast and lung carcinomas and malignant gliomas”,Cancer Res., 1995, vol. 55, pp. 3140-3148.
Koprivica V., et al, “EGFR activation mediates inhibition of axon regeneration by myelin and chondroitin sulfate proteoglycans”,Science, 2005, vol. 310, pp. 106-110.
Horizons in Cancer Therapeutics: From Bench to Bedside, Signal Transduction Inhibitors, 2001, 2(2), ISSN 1532-3048.
Slamon D.J., “Human breast cancer: Correlation of relapse and survival with amplification of HER-2
eu oncogene”,Science, 1987, vol. 235, pp. 177-182.
Slamon D.J et al; “Studies of the HER-2
eu proto-oncogene in human breast and ovarian cancer”,Science, 1989, vol. 244, pp. 707-712.
Hetzel D.J., “HER-2
eu expression: A major prognostic factor in endometrial cancer”,Gynecologic Oncology, 1992, vol. 47, pp. 179-185.
Kirsch D.G. et al.; “Targeting HER-2 in brain metastases from breast cancer”,Clinical Cancer Research, 2003, vol. 9, pp. 5435-5436.
Grossi P.M., “Efficacy of intracerebral microinfusion of trastuzumab in an athymic rat model of intracerebral metastatic breast cancer”,Clinical Cancer Research, 2003, vol. 9, pp. 5514-5520.
Wang X, et al., Nature, 2003, vol. 424, pp. 456-461.
Yeatman T.J., Nature Reviews Cancer, 2004, vol. 4(6), pp. 470-480.
Goldenberg-Furmanov M. et al., Cancer Research, 2004, vol. 64, pp. 1058-1064.
Shah N.P. et al., Science, 2004, vol. 305, pp. 399-401.
Donato N.J. et al., Blood, 2003, vol. 101(2), pp. 690-698.
Pardee A.B.,Science, 1989, vol. 246, pp. 603-608.
Nasmyth K.,Science, 1996, vol. 274, pp. 1643-1677.
Morgan D.O.,Ann. Rev. Cell Dev. Biol, 1997, vol. 13, pp. 261-291.
Draetta, G.,Trends in Biochem. Sci., 1990, vol. 15, pp. 378-382.
Sherr C.J., Cell, 1993, vol. 73, pp. 1059-1065.
Lee M. et al,Trends Genet., 1988, vol. 4, pp. 289-290.
Dunphy W.G.,Cell, 1988, vol. 54, pp. 423-431.
Gautier J.,Cell, 1988, vol. 54, pp. 433-439.
Cross F. et al.,Ann. Rev. Cell Biol., 1989, vol. 5, pp. 341-395.
Hunt, T.,Current Opinion in Cell Biology, 1989, vol. 1, pp. 268-274.
Nurse, P.,Nature, 1990, vol. 344, pp. 503-508.
Davis S.T. et al., “Prevention of chemotherapy-induced alopecia in rats by CDK inhibitors”,Science, 2001, vol. 291, pp. 134-137.
Jean Marx,Science, 2001, vol. 291, pp. 25-26.
Ross, R.,Nature, 1993, vol. 362, pp. 801-809.
Brooks E. et al., “CVT-313, a Specific and Potent Inhibitor of CDK2 That Prevents Neointimal Proliferation”,J. Biol. Chem., 1997, vol. 272(46), pp. 29207-29211.
Arnon R. et al., “Monoclonal Antibodies For Immunotargeting Of Drugs In Cancer Therapy”,Monoclonal Antibodies And Cancer Therapy, 1985, pp. 243-256.
Hellstrom K.E. et al., Antibodies For Drug Delivery,Controlled Drug Delivery(2nd Ed.), Robinson, et al. (eds.), pp. 623-653 (Marcel Dekker, Inc. 1987).
Thorpe P.E., “Antibody Carriers Of Cytotoxic Agents In Cancer Therapy: A Review”,Monoclonal Antibodies '84: Biological And Clinical Applications, 1985, pp. 475-506.
Mickelson J.W.,J. Med. Chem. 1996, vol. 39, pp. 4654-4666.
Chiu George
Connolly Peter J.
Emanuel Stuart
Huang Shenlin
Li Shengjian
Donnelly Laura A.
Janssen Pharmaceutica N.V.
Rahmani Niloofar
Seaman D. Margaret
LandOfFree
3-benzoimidazolyl-pyrazolopyridines useful in treating... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 3-benzoimidazolyl-pyrazolopyridines useful in treating..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 3-benzoimidazolyl-pyrazolopyridines useful in treating... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4146937